BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Type 2 Diabetes readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Type 2 Diabetes\, fro
 m ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05067621-114@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Semaglutide (Ozempic): Phase 2 readout est. (NCT05067621)
DESCRIPTION:Semaglutide (Ozempic)\, phase 2\, Type 2 Diabetes.\nStudy: Sema
 glutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes 
 and Metabolic Dysfunction-Associated Steatotic Liver Disease\nEstimated pr
 imary completion: December 2026. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/semaglutide-ozempic#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT05067621
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07472725-489@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:SHR-3167: Phase 2 readout est. (NCT07472725)
DESCRIPTION:SHR-3167\, phase 2\, Type 2 Diabetes.\nStudy: A Study Comparing
  Safety and Efficacy of SHR-3167 Fixed-Dose Titration and Individualized-D
 ose Titration in Adults With Type 2 Diabetes Inadequately Controlled With 
 Oral Antihyperglycemic Agents\nEstimated primary completion: December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/shr-3167#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07472725
URL:https://assetmemo.bio/drug/shr-3167#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07239440-431@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:DA-2811: Phase 2 readout est. (NCT07239440)
DESCRIPTION:DA-2811\, phase 2\, Type 2 Diabetes.\nStudy: Clinical Trial to 
 Evaluate the Efficacy and Safety of DA-2811 When Added to Ongoing BT-1 and
  BT-2 Combination Therapy in Patients With Type 2 Diabetes Who Have Inadeq
 uate Glycemic Control\nEstimated primary completion: December 2026. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/da-2811#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07239440
URL:https://assetmemo.bio/drug/da-2811#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05427084-307@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Invokana (Canagliflozin): Phase 2/3 readout est. (NCT05427084)
DESCRIPTION:Invokana (Canagliflozin)\, phase 2/3\, Type 2 Diabetes.\nStudy:
  Canagliflozin Targeting Vascular Inflammation\nEstimated primary completi
 on: December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ca
 nagliflozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT05427084
URL:https://assetmemo.bio/drug/canagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07059377-114@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Semaglutide (Ozempic): Phase 3 readout est. (NCT07059377)
DESCRIPTION:Semaglutide (Ozempic)\, phase 3\, Type 2 Diabetes.\nStudy: Sema
 glutide for Smoking Cessation in Patients With Diabetes\nEstimated primary
  completion: December 2026. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/semaglutide-ozempic#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07059377
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07093476-280@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Glucophage (metformin): Phase 3 readout est. (NCT07093476)
DESCRIPTION:Glucophage (metformin)\, phase 3\, Type 2 Diabetes.\nStudy: Eff
 icacy and Safety of Add-On Therapy With Empagliflozin in Patients With Typ
 e 2 Diabetes on a Background of Alogliptin and Metformin\nEstimated primar
 y completion: December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/metformin#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07093476
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07093476-299@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Nesina (Alogliptin): Phase 3 readout est. (NCT07093476)
DESCRIPTION:Nesina (Alogliptin)\, phase 3\, Type 2 Diabetes.\nStudy: Effica
 cy and Safety of Add-On Therapy With Empagliflozin in Patients With Type 2
  Diabetes on a Background of Alogliptin and Metformin\nEstimated primary c
 ompletion: December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/alogliptin#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07093476
URL:https://assetmemo.bio/drug/alogliptin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07093476-308@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Jardiance (Empagliflozin): Phase 3 readout est. (NCT07093476)
DESCRIPTION:Jardiance (Empagliflozin)\, phase 3\, Type 2 Diabetes.\nStudy: 
 Efficacy and Safety of Add-On Therapy With Empagliflozin in Patients With 
 Type 2 Diabetes on a Background of Alogliptin and Metformin\nEstimated pri
 mary completion: December 2026. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/empagliflozin#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07093476
URL:https://assetmemo.bio/drug/empagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07139535-198@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:RAY1225: Phase 3 readout est. (NCT07139535)
DESCRIPTION:RAY1225\, phase 3\, Type 2 Diabetes.\nStudy: A Study of RAY1225
  in Participants With Type 2 Diabetes Not Controlled With Diet and Exercis
 e Alone\nEstimated primary completion: 1 December 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/ray1225#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07139535
URL:https://assetmemo.bio/drug/ray1225#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07139548-198@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:RAY1225: Phase 3 readout est. (NCT07139548)
DESCRIPTION:RAY1225\, phase 3\, Type 2 Diabetes.\nStudy: A Study of RAY1225
  Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Partic
 ipants With Type 2 Diabetes\nEstimated primary completion: 1 December 2026
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/ray1225#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07139548
URL:https://assetmemo.bio/drug/ray1225#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05507892-307@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20261215
DTEND;VALUE=DATE:20261216
SUMMARY:Invokana (Canagliflozin): Phase 2 readout est. (NCT05507892)
DESCRIPTION:Invokana (Canagliflozin)\, phase 2\, Type 2 Diabetes.\nStudy: R
 enal Mechanism of SGLT2 Inhibition\nEstimated primary completion: 15 Decem
 ber 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/canaglifloz
 in#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5507892
URL:https://assetmemo.bio/drug/canagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07073768-305@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20261226
DTEND;VALUE=DATE:20261227
SUMMARY:Zafatek (Trelagliptin): Phase 3 readout est. (NCT07073768)
DESCRIPTION:Zafatek (Trelagliptin)\, phase 3\, Type 2 Diabetes.\nStudy: Com
 parison Between Efficacy of Trelagliptin and Sitagliptin in Type II Diabet
 ic Patients\nEstimated primary completion: 26 December 2026. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/trelagliptin#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07073768
URL:https://assetmemo.bio/drug/trelagliptin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06005012-114@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Semaglutide (Ozempic): Phase 2 readout est. (NCT06005012)
DESCRIPTION:Semaglutide (Ozempic)\, phase 2\, Type 2 Diabetes.\nStudy: Sema
 glutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity a
 nd T2DM\nEstimated primary completion: 31 December 2026. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06005012
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05464784-8091@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tipelukast: Phase 2 readout est. (NCT05464784)
DESCRIPTION:Tipelukast\, phase 2\, Type 2 Diabetes.\nStudy: MN-001 in Non-a
 lcoholic Fatty Liver Disease\, Type 2 Diabetes Mellitus\, and Hypertriglyc
 eridemia\nEstimated primary completion: 31 December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/tipelukast#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT05464784
URL:https://assetmemo.bio/drug/tipelukast#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06050577-11056@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Semaglutide (Rybelsus): Phase 2 readout est. (NCT06050577)
DESCRIPTION:Semaglutide (Rybelsus)\, phase 2\, Type 2 Diabetes.\nStudy: The
  Effect of Oral Semaglutide on Bone Turnover in Patients With T2D: a Rando
 mized Placebo-controlled Clinical Trial\nEstimated primary completion: 15 
 January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/semaglu
 tide-rybelsus#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06050577
URL:https://assetmemo.bio/drug/semaglutide-rybelsus#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06858839-143@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20270121
DTEND;VALUE=DATE:20270122
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT068588
 39)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Evaluation of Maridebart Cafraglutide in Adult Participants Without Type 
 2 Diabetes Mellitus Who Have Obesity or Are Overweight\nEstimated primary 
 completion: 21 January 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/maridebart-cafraglutide#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06858839
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06858878-143@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20270121
DTEND;VALUE=DATE:20270122
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT068588
 78)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With
  Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight\nEstimated pr
 imary completion: 21 January 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/maridebart-cafraglutide#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06858878
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07060456-185@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:ribupatide: Phase 3 readout est. (NCT07060456)
DESCRIPTION:ribupatide\, phase 3\, Type 2 Diabetes.\nStudy: Efficacy and Sa
 fety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal In
 sulin\nEstimated primary completion: February 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/ribupatide#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07060456
URL:https://assetmemo.bio/drug/ribupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07387003-443@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20270211
DTEND;VALUE=DATE:20270212
SUMMARY:GZR101: Phase 2 readout est. (NCT07387003)
DESCRIPTION:GZR101\, phase 2\, Type 2 Diabetes.\nStudy: Evaluate the Effica
 cy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes\nEst
 imated primary completion: 11 February 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/gzr101#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07387003
URL:https://assetmemo.bio/drug/gzr101#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07082114-195@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20270216
DTEND;VALUE=DATE:20270217
SUMMARY:HDM1002: Phase 3 readout est. (NCT07082114)
DESCRIPTION:HDM1002\, phase 3\, Type 2 Diabetes.\nStudy: A Phase 3 Study to
  Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Dia
 betes Mellitus\nEstimated primary completion: 16 February 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/hdm1002#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07082114
URL:https://assetmemo.bio/drug/hdm1002#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07502495-380@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Icovamenib: Phase 2 readout est. (NCT07502495)
DESCRIPTION:Icovamenib\, phase 2\, Type 2 Diabetes.\nStudy: Phase 2 Trial o
 f Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Gl
 ycemic Targets\nEstimated primary completion: March 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/icovamenib#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07502495
URL:https://assetmemo.bio/drug/icovamenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07156500-144@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20270330
DTEND;VALUE=DATE:20270331
SUMMARY:olatorepatide: Phase 3 readout est. (NCT07156500)
DESCRIPTION:olatorepatide\, phase 3\, Type 2 Diabetes.\nStudy: A Phase 3 St
 udy of HS-20094 in Patients With T2DM Inadequately Controlled With Diet an
 d Exercise Alone\nEstimated primary completion: 30 March 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/olatorepatide#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07156500
URL:https://assetmemo.bio/drug/olatorepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07156539-144@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20270330
DTEND;VALUE=DATE:20270331
SUMMARY:olatorepatide: Phase 3 readout est. (NCT07156539)
DESCRIPTION:olatorepatide\, phase 3\, Type 2 Diabetes.\nStudy: A Phase 3 St
 udy of HS-20094 in Patients With T2DM\nEstimated primary completion: 30 Ma
 rch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/olatorepati
 de#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7156539
URL:https://assetmemo.bio/drug/olatorepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07282743-274@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Utreglutide: Phase 2 readout est. (NCT07282743)
DESCRIPTION:Utreglutide\, phase 2\, Obesity.\nStudy: Efficacy and Safety of
  GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus\nEsti
 mated primary completion: April 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/utreglutide#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07282743
URL:https://assetmemo.bio/drug/utreglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07340320-223@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20270408
DTEND;VALUE=DATE:20270409
SUMMARY:VCT220: Phase 2 readout est. (NCT07340320)
DESCRIPTION:VCT220\, phase 2\, Type 2 Diabetes.\nStudy: A Study of CX11 Tab
 lets in Patients With Type 2 Diabetes Mellitus\nEstimated primary completi
 on: 8 April 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vct
 220#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07340320
URL:https://assetmemo.bio/drug/vct220#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06731075-335@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20270425
DTEND;VALUE=DATE:20270426
SUMMARY:ORMD-0801: Phase 3 readout est. (NCT06731075)
DESCRIPTION:ORMD-0801\, phase 3\, Type 2 Diabetes.\nStudy: A Phase 3 Study 
 to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 D
 iabetes Mellitus.\nEstimated primary completion: 25 April 2027. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/ormd-0801#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06731075
URL:https://assetmemo.bio/drug/ormd-0801#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07064486-200@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:BGM0504: Phase 3 readout est. (NCT07064486)
DESCRIPTION:BGM0504\, phase 3\, Type 2 Diabetes.\nStudy: A Study of BGM0504
  in Participants With Type 2 Diabetes in Indonesia\nEstimated primary comp
 letion: 30 April 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/bgm0504#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07064486
URL:https://assetmemo.bio/drug/bgm0504#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07677891-257@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:PG-102: Phase 2 readout est. (NCT07677891)
DESCRIPTION:PG-102\, phase 2\, Type 2 Diabetes.\nStudy: Phase II Study of S
 witching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes Mellitus\nEst
 imated primary completion: May 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/pg-102#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07677891
URL:https://assetmemo.bio/drug/pg-102#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07599410-185@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:ribupatide: Phase 2 readout est. (NCT07599410)
DESCRIPTION:ribupatide\, phase 2\, Type 2 Diabetes.\nStudy: A Research Stud
 y to Investigate the Efficacy and Safety of HRS9531 Tablets in Participant
 s With Type 2 Diabetes Mellitus\nEstimated primary completion: May 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ribupatide#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07599410
URL:https://assetmemo.bio/drug/ribupatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07613307-117@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT07613307)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Type 2 Diabetes.\nStudy: A 
 Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes Who
  Observe Ramadan Fasting\nEstimated primary completion: May 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/orforglipron#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07613307
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07598864-306@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0759886
 4)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3\, Type 2 Diabetes.\
 nStudy: "Dapagliflozin vs Dapagliflozin-Finerenone for Albuminuria in CKD 
 With Type 2 Diabetes"\nEstimated primary completion: 1 May 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/dapagliflozin#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07598864
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07220759-120@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20270512
DTEND;VALUE=DATE:20270513
SUMMARY:cagrilintide: Phase 3 readout est. (NCT07220759)
DESCRIPTION:cagrilintide\, phase 3\, Obesity.\nStudy: Weight Loss in People
  Living With Overweight or Obesity and Type 2 Diabetes Following Treatment
  With Cagrilintide\nEstimated primary completion: 12 May 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/cagrilintide#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07220759
URL:https://assetmemo.bio/drug/cagrilintide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07496177-455@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Berberine ursodeoxycholate (HTD1801): Phase 2 readout est. (NCT0749
 6177)
DESCRIPTION:Berberine ursodeoxycholate (HTD1801)\, phase 2\, Type 2 Diabete
 s.\nStudy: A Mechanistic Study on the Effect of HTD1801 Versus Placebo on 
 Kidney Function in Patients With Type 2 Diabetes and Chronic Kidney Diseas
 e.\nEstimated primary completion: 31 May 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/berberine-ursodeoxycholate-htd1801#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07496177
URL:https://assetmemo.bio/drug/berberine-ursodeoxycholate-htd1801#upcoming-
 events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07502508-380@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Icovamenib: Phase 2 readout est. (NCT07502508)
DESCRIPTION:Icovamenib\, phase 2\, Type 2 Diabetes.\nStudy: Phase 2 Trial o
 f Icovamenib in Participants With Type 2 Diabetes Mellitus Who Are Not Ach
 ieving Glycemic Targets While Using GLP-1-Based Therapy\nEstimated primary
  completion: June 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/icovamenib#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07502508
URL:https://assetmemo.bio/drug/icovamenib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07817251-121@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20270609
DTEND;VALUE=DATE:20270610
SUMMARY:CagriSema (cagrilintide/semaglutide): Phase 3 readout est. (NCT0781
 7251)
DESCRIPTION:CagriSema (cagrilintide/semaglutide)\, phase 3\, Type 2 Diabete
 s.\nStudy: Research Study on How People With Type 2 Diabetes Tolerate Swit
 ching From Semaglutide to Cagrisema\nEstimated primary completion: 9 June 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/cagrilintide-se
 maglutide#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07817251
URL:https://assetmemo.bio/drug/cagrilintide-semaglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07872436-223@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:VCT220: Phase 2 readout est. (NCT07872436)
DESCRIPTION:VCT220\, phase 2\, Type 2 Diabetes.\nStudy: A Study of VCT220 T
 ablets in Adults With Type 2 Diabetes and Inadequate Blood Glucose Control
 \nEstimated primary completion: 1 July 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/vct220#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07872436
URL:https://assetmemo.bio/drug/vct220#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07104383-178@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:VK2735: Phase 3 readout est. (NCT07104383)
DESCRIPTION:VK2735\, phase 3\, Obesity.\nStudy: VK2735 for Weight Managemen
 t Type 2 Diabetes Phase 3 (VANQUISH 2)\nEstimated primary completion: 1 Ju
 ly 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/vk2735#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07104383
URL:https://assetmemo.bio/drug/vk2735#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06972472-117@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT06972472)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Study of
  Orforglipron (LY3502970) in Participants With Obesity or Overweight and T
 ype 2 Diabetes\nEstimated primary completion: August 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/orforglipron#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT06972472
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06993792-117@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT06993792)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Obesity.\nStudy: A Master P
 rotocol for Orforglipron (LY3502970) in Participants With Obesity or Overw
 eight With and Without Type 2 Diabetes\nEstimated primary completion: Augu
 st 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/orforglipron
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT069
 93792
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07394114-196@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20270828
DTEND;VALUE=DATE:20270829
SUMMARY:HDM1005: Phase 3 readout est. (NCT07394114)
DESCRIPTION:HDM1005\, phase 3\, Type 2 Diabetes.\nStudy: A Study of HDM1005
  in Participants With Type 2 Diabetes Not Controlled With Diet and Exercis
 e Alone\nEstimated primary completion: 28 August 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/hdm1005#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07394114
URL:https://assetmemo.bio/drug/hdm1005#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07417306-196@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:HDM1005: Phase 3 readout est. (NCT07417306)
DESCRIPTION:HDM1005\, phase 3\, Type 2 Diabetes.\nStudy: A Study of HDM1005
  in Participants With T2DM Not Controlled With Metformin Alone or in Combi
 nation With a Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor\nEstimated 
 primary completion: 30 August 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/hdm1005#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07417306
URL:https://assetmemo.bio/drug/hdm1005#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04501406-291@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Actos (Pioglitazone): Phase 2 readout est. (NCT04501406)
DESCRIPTION:Actos (Pioglitazone)\, phase 2\, Type 2 Diabetes.\nStudy: Low-D
 ose Pioglitazone in Patients With NASH (AIM 2)\nEstimated primary completi
 on: 31 August 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/p
 ioglitazone#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT04501406
URL:https://assetmemo.bio/drug/pioglitazone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07139405-280@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Glucophage (metformin): Phase 2 readout est. (NCT07139405)
DESCRIPTION:Glucophage (metformin)\, phase 2\, Type 2 Diabetes.\nStudy: Tri
 Glytza®-01 Versus Metformin in Overweight and Obese Adults With Type 2 Di
 abetes and Inadequate Glycaemic Control Despite Metformin Therapy\nEstimat
 ed primary completion: 1 September 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/metformin#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07139405
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07415954-138@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20270903
DTEND;VALUE=DATE:20270904
SUMMARY:NNC0662-0419: Phase 2 readout est. (NCT07415954)
DESCRIPTION:NNC0662-0419\, phase 2\, Type 2 Diabetes.\nStudy: A Research St
 udy Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower 
 Blood Sugar in People With Type 2 Diabetes\nEstimated primary completion: 
 3 September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/nnc
 0662-0419#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07415954
URL:https://assetmemo.bio/drug/nnc0662-0419#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07659574-199@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20270924
DTEND;VALUE=DATE:20270925
SUMMARY:UBT251: Phase 3 readout est. (NCT07659574)
DESCRIPTION:UBT251\, phase 3\, Type 2 Diabetes.\nStudy: Phase III Study of 
 UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate
  Glycemic Control on Diet and Exercise Alone（UNIGUIDE-1）\nEstimated pr
 imary completion: 24 September 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/ubt251#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07659574
URL:https://assetmemo.bio/drug/ubt251#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07527650-232@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:HM15275: Phase 2 readout est. (NCT07527650)
DESCRIPTION:HM15275\, phase 2\, Type 2 Diabetes.\nStudy: Study to Evaluate 
 HM15275 in Subjects With Type 2 Diabetes Mellitus\nEstimated primary compl
 etion: October 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 hm15275#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07527650
URL:https://assetmemo.bio/drug/hm15275#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07628985-190@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Bofanglutide: Phase 3 readout est. (NCT07628985)
DESCRIPTION:Bofanglutide\, phase 3\, Type 2 Diabetes.\nStudy: BALANCE-DM2 S
 tudy of Bofanglutide in Adults With Type 2 Diabetes\nEstimated primary com
 pletion: October 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/bofanglutide#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07628985
URL:https://assetmemo.bio/drug/bofanglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07920939-489@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:SHR-3167: Phase 3 readout est. (NCT07920939)
DESCRIPTION:SHR-3167\, phase 3\, Type 2 Diabetes.\nStudy: Efficacy and Safe
 ty of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Ad
 ults With Insulin-Naive Type 2 Diabetes\nEstimated primary completion: Oct
 ober 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/shr-3167#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07920
 939
URL:https://assetmemo.bio/drug/shr-3167#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07668388-199@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20271004
DTEND;VALUE=DATE:20271005
SUMMARY:UBT251: Phase 2 readout est. (NCT07668388)
DESCRIPTION:UBT251\, phase 2\, Type 2 Diabetes.\nStudy: A Research Study Co
 mparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar 
 in People With Type 2 Diabetes\nEstimated primary completion: 4 October 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/ubt251#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07668388
URL:https://assetmemo.bio/drug/ubt251#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07400653-179@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20271012
DTEND;VALUE=DATE:20271013
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07400653)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t the Study Medicine (PF-08653944) in People With Obesity or Overweight an
 d Type 2 Diabetes (T2D)\nEstimated primary completion: 12 October 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/berobenatide#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07400653
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07755150-225@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20271020
DTEND;VALUE=DATE:20271021
SUMMARY:DA-302168S: Phase 2 readout est. (NCT07755150)
DESCRIPTION:DA-302168S\, phase 2\, Type 2 Diabetes.\nStudy: A Study to Eval
 uate the Efficacy and Safety of DA-302168S Tablets in Subjects With Type 2
  Diabetes\nEstimated primary completion: 20 October 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/da-302168s#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07755150
URL:https://assetmemo.bio/drug/da-302168s#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07619833-312@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Envlo (Enavogliflozin): Phase 3 readout est. (NCT07619833)
DESCRIPTION:Envlo (Enavogliflozin)\, phase 3\, Type 2 Diabetes.\nStudy: To 
 Evaluate the Efficacy and Safety of Initial Combination Therapy With DWP16
 001 and DWC202518 Compared to DWP16001 Monotherapy and DWC202518 Monothera
 py in Patients With Type 2 Diabetes Mellitus\nEstimated primary completion
 : November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/enav
 ogliflozin#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07619833
URL:https://assetmemo.bio/drug/enavogliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07379333-230@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:efpeglenatide: Phase 3 readout est. (NCT07379333)
DESCRIPTION:efpeglenatide\, phase 3\, Type 2 Diabetes.\nStudy: A Study to E
 valuate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes M
 ellitus Inadequately Controlled With Metformin and Dapagliflozin\nEstimate
 d primary completion: November 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/efpeglenatide#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07379333
URL:https://assetmemo.bio/drug/efpeglenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03811561-114@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20271107
DTEND;VALUE=DATE:20271108
SUMMARY:Semaglutide (Ozempic): Phase 3 readout est. (NCT03811561)
DESCRIPTION:Semaglutide (Ozempic)\, phase 3\, Type 2 Diabetes.\nStudy: A Re
 search Study to Look at How Semaglutide Compared to Placebo Affects Diabet
 ic Eye Disease in People With Type 2 Diabetes\nEstimated primary completio
 n: 7 November 2027. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/s
 emaglutide-ozempic#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT03811561
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07923357-487@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:SAL0150: Phase 2 readout est. (NCT07923357)
DESCRIPTION:SAL0150\, phase 2\, Type 2 Diabetes.\nStudy: A Phase 2 Study to
  Evaluate the Efficacy\, Safety\, and Pharmacokinetics of SAL0150 Tablets 
 in Subjects With Type 2 Diabetes Mellitus\nEstimated primary completion: 3
 0 November 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/sal0
 150#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07923357
URL:https://assetmemo.bio/drug/sal0150#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06739122-127@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Trulicity (dulaglutide): Phase 3 readout est. (NCT06739122)
DESCRIPTION:Trulicity (dulaglutide)\, phase 3\, Type 2 Diabetes.\nStudy: A 
 Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participan
 ts With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)\nEstimated primary comp
 letion: December 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/dulaglutide#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06739122
URL:https://assetmemo.bio/drug/dulaglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07684144-143@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20271226
DTEND;VALUE=DATE:20271227
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT076841
 44)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Obesity.\nStudy:
  Extension Trial to Evaluate the Long-term Efficacy\, Safety\, and Tolerab
 ility of Maridebart Cafraglutide (MARITIME-2-EXTENSION)\nEstimated primary
  completion: 26 December 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/maridebart-cafraglutide#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07684144
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07296484-512@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:clofutriben: Phase 2 readout est. (NCT07296484)
DESCRIPTION:clofutriben\, phase 2\, Type 2 Diabetes.\nStudy: Trial Against 
 INtractable Type 2 Diabetes (CAPTAIN-T2D)\nEstimated primary completion: 3
 1 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/clof
 utriben#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07296484
URL:https://assetmemo.bio/drug/clofutriben#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07913061-489@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:SHR-3167: Phase 3 readout est. (NCT07913061)
DESCRIPTION:SHR-3167\, phase 3\, Type 2 Diabetes.\nStudy: A Study Comparing
  SHR-3167 With Insulin Degludec in Adults With Type 2 Diabetes Currently T
 reated With Basal Insulin\nEstimated primary completion: January 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/shr-3167#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07913061
URL:https://assetmemo.bio/drug/shr-3167#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07754461-119@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20280117
DTEND;VALUE=DATE:20280118
SUMMARY:survodutide: Phase 3 readout est. (NCT07754461)
DESCRIPTION:survodutide\, phase 3\, Type 2 Diabetes.\nStudy: A Study to Tes
 t Whether Survodutide Helps People With Type 2 Diabetes Control Their Bloo
 d Sugar\nEstimated primary completion: 17 January 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/survodutide#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07754461
URL:https://assetmemo.bio/drug/survodutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07112872-158@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20280205
DTEND;VALUE=DATE:20280206
SUMMARY:Tifeglipron: Phase 2 readout est. (NCT07112872)
DESCRIPTION:Tifeglipron\, phase 2\, Type 2 Diabetes.\nStudy: A Study to Com
 pare Different Doses of Tifeglipron (RO7795081) With Placebo or Semaglutid
 e in People With Type 2 Diabetes\nEstimated primary completion: 5 February
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/tifeglipron#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT071128
 72
URL:https://assetmemo.bio/drug/tifeglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07564414-121@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20280223
DTEND;VALUE=DATE:20280224
SUMMARY:CagriSema (cagrilintide/semaglutide): Phase 3 readout est. (NCT0756
 4414)
DESCRIPTION:CagriSema (cagrilintide/semaglutide)\, phase 3\, Obesity.\nStud
 y: A Research Study to Look at How Two Different Doses of CagriSema and On
 e Dose of Semaglutide Help People Living With Obesity With or Without Type
  2 Diabetes Lose Weight\nEstimated primary completion: 23 February 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/cagrilintide-semagluti
 de#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7564414
URL:https://assetmemo.bio/drug/cagrilintide-semaglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07670416-159@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20280224
DTEND;VALUE=DATE:20280225
SUMMARY:enicepatide: Phase 3 readout est. (NCT07670416)
DESCRIPTION:enicepatide\, phase 3\, Obesity.\nStudy: A Study to Evaluate th
 e Effects of Enicepatide in Participants With Obesity or Overweight\, With
  or Without Type 2 Diabetes\nEstimated primary completion: 24 February 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/enicepatide#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07670416
URL:https://assetmemo.bio/drug/enicepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07653477-199@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:UBT251: Phase 3 readout est. (NCT07653477)
DESCRIPTION:UBT251\, phase 3\, Type 2 Diabetes.\nStudy: Phase III Study of 
 UBT251 Injection in Patients With Type 2 Diabetes With Inadequate Glycemic
  Control on Metformin ± Sulfonylurea/SGLT2 Inhibitor Therapy (UNIGUIDE-2)
 \nEstimated primary completion: 29 February 2028. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/ubt251#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07653477
URL:https://assetmemo.bio/drug/ubt251#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07219602-401@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Obicetrapib: Phase 3 readout est. (NCT07219602)
DESCRIPTION:Obicetrapib\, phase 3\, Type 2 Diabetes.\nStudy: A Study to Eva
 luate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or 
 Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering The
 rapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome\nEstim
 ated primary completion: March 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/obicetrapib#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07219602
URL:https://assetmemo.bio/drug/obicetrapib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07775404-148@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20280406
DTEND;VALUE=DATE:20280407
SUMMARY:elecoglipron: Phase 3 readout est. (NCT07775404)
DESCRIPTION:elecoglipron\, phase 3\, Obesity.\nStudy: A Study to Investigat
 e the Efficacy and Safety of Elecoglipron in Asian Participants With Obesi
 ty or Overweight With or Without Type 2 Diabetes Mellitus\nEstimated prima
 ry completion: 6 April 2028. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/elecoglipron#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07775404
URL:https://assetmemo.bio/drug/elecoglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07563699-114@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Semaglutide (Ozempic): Phase 1/2 readout est. (NCT07563699)
DESCRIPTION:Semaglutide (Ozempic)\, phase 1/2\, Type 2 Diabetes.\nStudy: Sa
 fety\, Tolerability and Efficacy of Semaglutide Depot in Subjects With Typ
 e-2 Diabetes Mellitus\nEstimated primary completion: May 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07563699
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07662213-148@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20280523
DTEND;VALUE=DATE:20280524
SUMMARY:elecoglipron: Phase 3 readout est. (NCT07662213)
DESCRIPTION:elecoglipron\, phase 3\, Type 2 Diabetes.\nStudy: A Study to Fi
 nd Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Me
 llitus by Comparing it With Semaglutide\, a Medicine Already Used to Treat
  Type 2 Diabetes Mellitus\nEstimated primary completion: 23 May 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/elecoglipron#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT07662213
URL:https://assetmemo.bio/drug/elecoglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07664553-148@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20280523
DTEND;VALUE=DATE:20280524
SUMMARY:elecoglipron: Phase 3 readout est. (NCT07664553)
DESCRIPTION:elecoglipron\, phase 3\, Type 2 Diabetes.\nStudy: A Phase III S
 tudy to Investigate the Efficacy and Safety of Elecoglipron Compared With 
 Placebo in Adults With Type 2 Diabetes Mellitus on Background Insulin\nEst
 imated primary completion: 23 May 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/elecoglipron#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07664553
URL:https://assetmemo.bio/drug/elecoglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07931495-133@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20280605
DTEND;VALUE=DATE:20280606
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07931495)
DESCRIPTION:zenagamtide\, phase 3\, Type 2 Diabetes.\nStudy: A Research Stu
 dy Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight C
 ompared to Placebo in People With Type 2 Diabetes Treated With Diet and Ex
 ercise\nEstimated primary completion: 5 June 2028. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/zenagamtide#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07931495
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07743450-211@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:ASC30: Phase 3 readout est. (NCT07743450)
DESCRIPTION:ASC30\, phase 3\, Obesity.\nStudy: A Study of Once-daily Oral A
 SC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesit
 y or Overweight With Type 2 Diabetes\nEstimated primary completion: July 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/asc30#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07743450
URL:https://assetmemo.bio/drug/asc30#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07931573-133@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20280704
DTEND;VALUE=DATE:20280705
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07931573)
DESCRIPTION:zenagamtide\, phase 3\, Type 2 Diabetes.\nStudy: AMBITION 3: A 
 Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lo
 wers Blood Sugar and Body Weight Compared to Semaglutide in People With Ty
 pe 2 Diabetes Treated With Metformin\, SGLT2i\, or Both\nEstimated primary
  completion: 4 July 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/zenagamtide#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07931573
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07662109-148@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20280705
DTEND;VALUE=DATE:20280706
SUMMARY:elecoglipron: Phase 3 readout est. (NCT07662109)
DESCRIPTION:elecoglipron\, phase 3\, Type 2 Diabetes.\nStudy: A Phase III S
 tudy to Investigate the Efficacy and Safety of the Combination of Elecogli
 pron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus\nEstimated 
 primary completion: 5 July 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/elecoglipron#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07662109
URL:https://assetmemo.bio/drug/elecoglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07662135-148@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20280713
DTEND;VALUE=DATE:20280714
SUMMARY:elecoglipron: Phase 3 readout est. (NCT07662135)
DESCRIPTION:elecoglipron\, phase 3\, Type 2 Diabetes.\nStudy: A Phase III S
 tudy to Investigate the Efficacy and Safety of Elecoglipron Compared With 
 Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Functio
 n on Background Dapagliflozin\nEstimated primary completion: 13 July 2028.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/elecoglipron#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07662135
URL:https://assetmemo.bio/drug/elecoglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07662044-148@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20280714
DTEND;VALUE=DATE:20280715
SUMMARY:elecoglipron: Phase 3 readout est. (NCT07662044)
DESCRIPTION:elecoglipron\, phase 3\, Type 2 Diabetes.\nStudy: A Phase III S
 tudy to Investigate the Efficacy and Safety of Elecoglipron Alone or in Co
 mbination With Dapagliflozin Compared With Placebo in Adults With Type 2 D
 iabetes Mellitus\nEstimated primary completion: 14 July 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/elecoglipron#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07662044
URL:https://assetmemo.bio/drug/elecoglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07662044-306@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20280714
DTEND;VALUE=DATE:20280715
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 3 readout est. (NCT0766204
 4)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 3\, Type 2 Diabetes.\
 nStudy: A Phase III Study to Investigate the Efficacy and Safety of Elecog
 lipron Alone or in Combination With Dapagliflozin Compared With Placebo in
  Adults With Type 2 Diabetes Mellitus\nEstimated primary completion: 14 Ju
 ly 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/dapagliflozi
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 662044
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07931599-133@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20280724
DTEND;VALUE=DATE:20280725
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07931599)
DESCRIPTION:zenagamtide\, phase 3\, Type 2 Diabetes.\nStudy: A Research Stu
 dy Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Su
 gar and Body Weight Compared to Semaglutide at Lower Dose Levels in People
  With Type 2 Diabetes Treated With Metformin\, Sodium-Glucose Cotransporte
 r 2 Inhibitors (SGLT2i)\, or Both\nEstimated primary completion: 24 July 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/zenagamtide#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07931599
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07351045-159@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20280724
DTEND;VALUE=DATE:20280725
SUMMARY:enicepatide: Phase 3 readout est. (NCT07351045)
DESCRIPTION:enicepatide\, phase 3\, Obesity.\nStudy: A Clinical Study to Ev
 aluate the Effects of Enicepatide (RO7795068) in Participants With Obesity
  or Overweight Without Type 2 Diabetes\nEstimated primary completion: 24 J
 uly 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/enicepatide
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT073
 51045
URL:https://assetmemo.bio/drug/enicepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07931547-133@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07931547)
DESCRIPTION:zenagamtide\, phase 3\, Type 2 Diabetes.\nStudy: A Research Stu
 dy Investigating How Well Zenagamtide Lowers Blood Sugar and Body Weight C
 ompared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disea
 se Treated With Once Daily Basal Insulin Alone or in Combination With Metf
 ormin\, SGLT2i\, or Both\nEstimated primary completion: 31 July 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/zenagamtide#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07931547
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07797335-133@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07797335)
DESCRIPTION:zenagamtide\, phase 3\, Type 2 Diabetes.\nStudy: AMBITION 7: A 
 Research Study Investigating How Well Zenagamtide Lowers Blood Sugar and B
 ody Weight Compared to Insulin Glargine in People With Type 2 Diabetes and
  Increased Risk of Diseases That Affect the Heart and Blood Vessels Treate
 d With 1-3 Other Diabetes Medications\nEstimated primary completion: 31 Ju
 ly 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/zenagamtide#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0779
 7335
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07667803-148@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:elecoglipron: Phase 3 readout est. (NCT07667803)
DESCRIPTION:elecoglipron\, phase 3\, Obesity.\nStudy: A Master Protocol to 
 Investigate Efficacy and Safety of Elecoglipron in Participants With Obesi
 ty or Overweight With or Without T2DM\nEstimated primary completion: 31 Ju
 ly 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/elecoglipron
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT076
 67803
URL:https://assetmemo.bio/drug/elecoglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07533175-133@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20280807
DTEND;VALUE=DATE:20280808
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07533175)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: AMAZE 2: A Research St
 udy Investigating How Well the Medicine NNC0487-0111 Helps People With Exc
 ess Body Weight and Type 2 Diabetes Lose Weight\nEstimated primary complet
 ion: 7 August 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/z
 enagamtide#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07533175
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07351058-159@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20280807
DTEND;VALUE=DATE:20280808
SUMMARY:enicepatide: Phase 3 readout est. (NCT07351058)
DESCRIPTION:enicepatide\, phase 3\, Obesity.\nStudy: A Clinical Study to Ev
 aluate the Effects of Enicepatide (RO7795068) in Participants With Obesity
  or Overweight and Type 2 Diabetes\nEstimated primary completion: 7 August
  2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/enicepatide#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT073510
 58
URL:https://assetmemo.bio/drug/enicepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07915609-179@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20280821
DTEND;VALUE=DATE:20280822
SUMMARY:Berobenatide: Phase 3 readout est. (NCT07915609)
DESCRIPTION:Berobenatide\, phase 3\, Obesity.\nStudy: A Study to Learn Abou
 t Berobenatide Given Once Weekly in Adults With Knee Osteoarthritis and Ov
 erweight or Obesity With or Without Type 2 Diabetes (VESPER-OA 2)\nEstimat
 ed primary completion: 21 August 2028. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/berobenatide#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07915609
URL:https://assetmemo.bio/drug/berobenatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07654374-177@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:aleniglipron: Phase 3 readout est. (NCT07654374)
DESCRIPTION:aleniglipron\, phase 3\, Obesity.\nStudy: A Study of Aleniglipr
 on in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCO
 MPLISH-2)\nEstimated primary completion: September 2028. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/aleniglipron#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07654374
URL:https://assetmemo.bio/drug/aleniglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07866066-143@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20280906
DTEND;VALUE=DATE:20280907
SUMMARY:MariTide (maridebart cafraglutide): Phase 3 readout est. (NCT078660
 66)
DESCRIPTION:MariTide (maridebart cafraglutide)\, phase 3\, Type 2 Diabetes.
 \nStudy: Maridebart Cafraglutide Versus Semaglutide in Participants With T
 ype 2 Diabetes\nEstimated primary completion: 6 September 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/maridebart-cafraglutide#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07866066
URL:https://assetmemo.bio/drug/maridebart-cafraglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07743983-200@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:BGM0504: Phase 3 readout est. (NCT07743983)
DESCRIPTION:BGM0504\, phase 3\, Obesity.\nStudy: A Study of BGM0504 in Earl
 y T2DM With Obesity\nEstimated primary completion: 30 September 2028. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/bgm0504#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07743983
URL:https://assetmemo.bio/drug/bgm0504#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07357415-118@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:retatrutide: Phase 3 readout est. (NCT07357415)
DESCRIPTION:retatrutide\, phase 3\, Obesity.\nStudy: A Study of Retatrutide
  (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or O
 verweight\nEstimated primary completion: October 2028. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/retatrutide#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07357415
URL:https://assetmemo.bio/drug/retatrutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07868939-178@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:VK2735: Phase 3 readout est. (NCT07868939)
DESCRIPTION:VK2735\, phase 3\, Obesity.\nStudy: Oral VK2735 for Weight Mana
 gement in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)\nEstima
 ted primary completion: October 2028. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/vk2735#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07868939
URL:https://assetmemo.bio/drug/vk2735#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06976619-116@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20281030
DTEND;VALUE=DATE:20281031
SUMMARY:Liraglutide (Victoza): Phase 2 readout est. (NCT06976619)
DESCRIPTION:Liraglutide (Victoza)\, phase 2\, Type 2 Diabetes.\nStudy: The 
 Effect of Glycemic Control and of GLP-1 Receptor Agonism on Islet GLP-1 in
  People With Type 1 and Type 2 Diabetes\nEstimated primary completion: 30 
 October 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/liraglu
 tide-victoza#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06976619
URL:https://assetmemo.bio/drug/liraglutide-victoza#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07428746-114@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Semaglutide (Ozempic): Phase 3 readout est. (NCT07428746)
DESCRIPTION:Semaglutide (Ozempic)\, phase 3\, Type 2 Diabetes.\nStudy: Inve
 stigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Femal
 e Adults With Diabetes\nEstimated primary completion: November 2028. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/semaglutide-ozempic#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07428746
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07581145-114@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Semaglutide (Ozempic): Phase 3 readout est. (NCT07581145)
DESCRIPTION:Semaglutide (Ozempic)\, phase 3\, Type 2 Diabetes.\nStudy: Effe
 ct of Semaglutide on Healing of Foot Ulcers in Type 2 Diabetes Patients\nE
 stimated primary completion: December 2028. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07581145
URL:https://assetmemo.bio/drug/semaglutide-ozempic#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07902726-306@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Farxiga / Forxiga (Dapagliflozin): Phase 2 readout est. (NCT0790272
 6)
DESCRIPTION:Farxiga / Forxiga (Dapagliflozin)\, phase 2\, Type 2 Diabetes.\
 nStudy: Adding Acetazolamide on Top of SGLT2 Inhibition in Persons With Ty
 pe 2 Diabetes\nEstimated primary completion: 1 December 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/dapagliflozin#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07902726
URL:https://assetmemo.bio/drug/dapagliflozin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07400107-133@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20281219
DTEND;VALUE=DATE:20281220
SUMMARY:zenagamtide: Phase 3 readout est. (NCT07400107)
DESCRIPTION:zenagamtide\, phase 3\, Obesity.\nStudy: AMAZE 8: A Research St
 udy Investigating How Well the Medicine NNC0487-0111 Compared to Semagluti
 de Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight\nE
 stimated primary completion: 19 December 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/zenagamtide#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07400107
URL:https://assetmemo.bio/drug/zenagamtide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07889648-159@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20290402
DTEND;VALUE=DATE:20290403
SUMMARY:enicepatide: Phase 3 readout est. (NCT07889648)
DESCRIPTION:enicepatide\, phase 3\, Type 2 Diabetes.\nStudy: A Clinical Stu
 dy to Evaluate the Effects of Enicepatide Versus Tirzepatide in Participan
 ts With Type 2 Diabetes and Inadequate Blood Sugar Control on Oral Glucose
 -Lowering Medications\nEstimated primary completion: 2 April 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/enicepatide#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07889648
URL:https://assetmemo.bio/drug/enicepatide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06246799-115@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Tirzepatide (Mounjaro): Phase 3 readout est. (NCT06246799)
DESCRIPTION:Tirzepatide (Mounjaro)\, phase 3\, Type 2 Diabetes.\nStudy: Com
 parative Effectiveness of Two Initial Combination Therapies in Patients Wi
 th Recent Onset Diabetes\nEstimated primary completion: 30 April 2029. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/tirzepatide-mounjaro#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0624679
 9
URL:https://assetmemo.bio/drug/tirzepatide-mounjaro#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06246799-291@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Actos (Pioglitazone): Phase 3 readout est. (NCT06246799)
DESCRIPTION:Actos (Pioglitazone)\, phase 3\, Type 2 Diabetes.\nStudy: Compa
 rative Effectiveness of Two Initial Combination Therapies in Patients With
  Recent Onset Diabetes\nEstimated primary completion: 30 April 2029. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/pioglitazone#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06246799
URL:https://assetmemo.bio/drug/pioglitazone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07083154-183@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20290801
DTEND;VALUE=DATE:20290802
SUMMARY:mazdutide: Phase 3 readout est. (NCT07083154)
DESCRIPTION:mazdutide\, phase 3\, Type 2 Diabetes.\nStudy: Mazdutide in Typ
 e 2 Diabetes With Early-Stage Cognitive Impairment (LIGHT-COG Study)\nEsti
 mated primary completion: 1 August 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/mazdutide#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07083154
URL:https://assetmemo.bio/drug/mazdutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07282613-121@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20290907
DTEND;VALUE=DATE:20290908
SUMMARY:CagriSema (cagrilintide/semaglutide): Phase 3 readout est. (NCT0728
 2613)
DESCRIPTION:CagriSema (cagrilintide/semaglutide)\, phase 3\, Type 2 Diabete
 s.\nStudy: A Research Study to See How Much CagriSema Lowers Blood Sugar a
 nd Body Weight Compared to Placebo in Children and Adolescents With Type 2
  Diabetes\nEstimated primary completion: 7 September 2029. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/cagrilintide-semaglutide#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07282613
URL:https://assetmemo.bio/drug/cagrilintide-semaglutide#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07064473-369@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20291214
DTEND;VALUE=DATE:20291215
SUMMARY:Vicadrostat: Phase 3 readout est. (NCT07064473)
DESCRIPTION:Vicadrostat\, phase 3\, Type 2 Diabetes.\nStudy: EASi-PROTKT™
  - A Study to Test Vicadrostat (BI 690517) Taken Together With Empaglifloz
 in in People With Type 2 Diabetes\, High Blood Pressure\, and Cardiovascul
 ar Disease\nEstimated primary completion: 14 December 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/vicadrostat#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07064473
URL:https://assetmemo.bio/drug/vicadrostat#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07668336-117@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Foundayo (orforglipron): Phase 3 readout est. (NCT07668336)
DESCRIPTION:Foundayo (orforglipron)\, phase 3\, Type 2 Diabetes.\nStudy: A 
 Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric P
 articipants With Type 2 Diabetes\nEstimated primary completion: March 2030
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/orforglipron#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07668336
URL:https://assetmemo.bio/drug/orforglipron#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07303803-294@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20301201
DTEND;VALUE=DATE:20301202
SUMMARY:Bilessglu (Chiglitazar): Phase 2 readout est. (NCT07303803)
DESCRIPTION:Bilessglu (Chiglitazar)\, phase 2\, Type 2 Diabetes.\nStudy: A 
 Study of Chiglitazar in Patients With Metabolic Dysfunction-associated Ste
 atohepatitis and Type 2 Diabetes Mellitus\nEstimated primary completion: 1
  December 2030. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/chigl
 itazar#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07303803
URL:https://assetmemo.bio/drug/chiglitazar#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07288749-281@assetmemo.bio
DTSTAMP:20261121T004023Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Amaryl (glimepiride): Phase 3 readout est. (NCT07288749)
DESCRIPTION:Amaryl (glimepiride)\, phase 3\, Type 2 Diabetes.\nStudy: Effic
 acy Evaluation of Glimepiride in Patients With Type 2 Diabetes Mellitus an
 d Chronic Heart Failure With Reduced Ejection Fraction.\nEstimated primary
  completion: 31 December 2030. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/glimepiride#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07288749
URL:https://assetmemo.bio/drug/glimepiride#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
